Aurinia Pharmaceuticals (AUPH) – Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Aurinia Pharmaceuticals (NASDAQ: AUPH):

• 11/7/2026 – Aurinia Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 11/4/2026 – Aurinia Pharmaceuticals was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
• 11/2/2026 – Aurinia Pharmaceuticals had its price target raised by Royal Bank Of Canada from $16.00 to $18.00. They now have a “sector perform” rating on the stock.
• 10/22/2026 – Aurinia Pharmaceuticals was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 10/21/2026 – Aurinia Pharmaceuticals had its price target raised by TD Cowen from $17.00 to $18.00. They now have a “buy” rating on the stock.

Aurinia Pharmaceuticals Stock Performance

Shares of NASDAQ AUPH traded down $0.42 during trading hours on Wednesday, hitting $15.88. 188,313 shares of the stock were exchanged, compared to its average volume of 1,145,314. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.12 and a quick ratio of 5.67. The company’s 50 day moving average is $16.49 and its 200 day moving average is $15.70. The firm has a market capitalization of $2.13 billion, a P/E ratio of 6.93 and a beta of 1.40. Aurinia Pharmaceuticals Inc has a one year low of $13.52 and a one year high of $19.25.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Friday, October 30th. The biotechnology company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.22 by $0.01. Aurinia Pharmaceuticals had a net margin of 97.68% and a return on equity of 22.99%. The firm had revenue of $83.70 million for the quarter, compared to the consensus estimate of $83.61 million. On average, research analysts expect that Aurinia Pharmaceuticals Inc will post 0.97 EPS for the current year.

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases. The Canadian company’s work has centered on therapies for conditions that can affect the kidneys and other organs. Its lead product, Lupkynis (voclosporin), is an oral medicine approved in the United States to treat adults with active lupus nephritis, a kidney complication of systemic lupus erythematosus. It is used in combination with background immunosuppressive therapy. Aurinia, formerly known as Isotechnika, developed voclosporin as a treatment for lupus nephritis.